Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart monitor aims to keep patients out of hospital

NCT ID NCT06641921

Disease control Sponsor: Seerlinq s. r. o. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a remote monitoring system called Seerlinq HeartCore in 330 heart failure patients. Participants used a device at home to measure heart function and report symptoms. The goal was to see if this approach could reduce hospitalizations and deaths over 6 months. The results could improve how doctors manage heart failure remotely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Seerlinq HeartCore telemedical monitoring system (device)
What this could lead to
If successful, this could show that remote monitoring helps heart failure patients avoid hospital stays and live longer at home.
What could go wrong
This is a single-arm trial without a comparison group, so benefits may be due to other factors. The device is not a cure and requires ongoing medication adjustments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

330 people

The number who actually took part.

Started

May 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Males and females aged ≥ 18 years. 2. Able to understand, and willing to provide written informed consent. 3. Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study. 4. Diagnosis of chronic heart failure in NYHA class II or III 5. Able to stand for 2 minutes 6. Access to necessary resources for participating in a technology-based intervention (smartphone, blood pressure monitor, internet access). Exclusion Criteria The participant may not enter the study if ANY of the following apply: 1. Use of other services for telemedical monitoring for heart failure. 2. Renal failure with a Glomerular Filtration Rate (GFR) \<25 ml/min or requiring renal replacement therapy. 3. Pregnancy, female participant lactating or planning pregnancy during the course of the trial. 4. Complex congenital heart disease 5. Subjects with known pulmonary hypertension (WHO category 1 or 3/4/5) 6. Inability to perform regular measurements alone or with help of a caregiver. 7. Other possible unforeseen medical conditions that the investigator deems unsafe for study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Remote monitoring

Contacts and locations

Locations

  • Premedix Clinic

    Bratislava, Nové Mesto, 831 01, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.